Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKinsey
Merck
Express Scripts
Baxter
US Department of Justice
AstraZeneca
McKesson
Mallinckrodt

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021172

« Back to Dashboard

NDA 021172 describes NOVOLOG MIX 70/30 PENFILL, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. Additional details are available on the NOVOLOG MIX 70/30 PENFILL profile page.

The generic ingredient in NOVOLOG MIX 70/30 PENFILL is insulin aspart protamine recombinant; insulin aspart recombinant. There are thirty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the insulin aspart protamine recombinant; insulin aspart recombinant profile page.
Pharmacology for NDA: 021172
Ingredient-typeInsulin
Suppliers and Packaging for NDA: 021172
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 NDA Novo Nordisk 0169-3685 N 0169-3685-12
NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 NDA Novo Nordisk 0169-3685 N 0169-3685-92

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)
Approval Date:Nov 1, 2001TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;SUBCUTANEOUSStrength210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)
Approval Date:Nov 1, 2001TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;SUBCUTANEOUSStrength210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)
Approval Date:Nov 1, 2001TE:RLD:No

Expired US Patents for NDA 021172

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-001 Nov 1, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-001 Nov 1, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Novo Nordisk Inc NOVOLOG MIX 70/30 FLEXPEN insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-004 May 3, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-001 Nov 1, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Johnson and Johnson
US Army
Covington
Harvard Business School
Medtronic
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.